Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ISRCTN13376195
ISRCTN13376195Active, not recruitingPhase 1

A Phase I, open-label, multi-center, pharmacokinetic, pharmacodynamic and safety study of tenecteplase in adult patients with acute ischemic stroke

Roche (United States)0 sites20 target enrollmentStarted: May 16, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
20
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Age =18 years at the time of signing the Informed Consent Form
  • •2. Clinical diagnosis of AIS based on signs and symptoms consistent with the diagnosis of an acute anterior circulation ischemic stroke, the persistence of neurologic deficit(s), and findings on computed tomographic (CT) scan or magnetic resonance imaging (MRI) with gradient echo sequences (GRE) sequence of the brain supportive of an AIS diagnosis
  • •3. Time from symptom onset to study drug administration is <4.5 hours

Exclusion Criteria

  • •1. Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 30 days after tenecteplase administration
  • •2. Active internal bleeding; evidence of intracranial haemorrhage on neuroimaging at screening
  • •3. Gastrointestinal haemorrhage within 21 days of screening
  • •4. Known hereditary or acquired haemorrhagic diathesis or coagulation factor deficiency
  • •5. Use of one of the novel oral anticoagulants, such as direct thrombin inhibitors or direct factor Xa inhibitors, within the last 48 hours (e.g., dabigatran, rivaroxaban, apixaban, edoxaban)
  • •6. Treatment with a thrombolytic within the last 3 months prior to dosing
  • •7. Intracranial neoplasm (except small meningioma), arteriovenous malformation, or aneurysm
  • •8. History of malignancy, including solid tumour and haematological malignancies, except basal cell carcinoma, in situ squamous cell carcinoma of the skin, and in situ carcinoma of the cervix that has been previously completely excised with documented, clear margins
  • •9. Severe, uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg)
  • •10. Clot retrieval attempted using a neurothrombectomy device prior to dosing
  • •11. History of acute ischemic stroke in the last 90 days
  • •12. History of haemorrhagic stroke
  • •13. Intracranial or intraspinal surgery or trauma within 2 months

Investigators

Sponsor
Roche (United States)

Similar Trials

Not yet recruiting
Not Applicable
A phase I, multi-center, open-label, drug-drug interaction study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on TKI258 (dovitinib) pharmacokinetics in patients with advanced solid tumors.advanced cancersolid tumors10027655
NL-OMON39285ovartis12
Active, not recruiting
Phase 1
A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (= 65 years) patients with essential thrombocythaemia.Xagrid is an antineoplasic indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
EUCTR2004-004058-20-ESShire Pharmaceutical Development Limited24
Active, not recruiting
Phase 1
A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (= 65 years) patients with essential thrombocythaemia.Xagrid is an antineoplasic indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
EUCTR2004-004058-20-GBShire Pharmaceutical Development Limited24
Active, not recruiting
Not Applicable
A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (= 65 years) patients with essential thrombocythaemia.Xagrid is an antineoplasic indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
EUCTR2004-004058-20-SEShire Pharmaceutical Development Limited24
Active, not recruiting
Not Applicable
A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (= 65 years) patients with essential thrombocythaemia.Xagrid is an antineoplasic indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
EUCTR2004-004058-20-DEShire Pharmaceutical Development Limited24